Clinicians traditionally define preeclampsia as a hypertensive disorder occurring after 20 weeks of gestation. However, the manifestation of early-onset preeclampsia before this threshold acts as a vital diagnostic signal for gestational trophoblastic disease (GTD). Specifically, this rare clinical presentation requires immediate investigation to rule out molar pregnancies, triploidy, or underlying renal pathology.

A recent case report highlighted a 15-year-old adolescent who presented with vaginal bleeding and persistent nausea. Upon admission, she showed clear signs of hypertension and proteinuria. Further diagnostic imaging and laboratory tests confirmed a complete hydatidiform mole. Unfortunately, the patient also developed grade IV hypovolemic shock. This complication required urgent uterine evacuation and intensive care management for uterine atony. Furthermore, clinicians identified pulmonary metastases during the staging process, necessitating systemic chemotherapy.

The Clinical Significance of Early-onset Preeclampsia

In many instances, early-onset preeclampsia serves as the initial clinical manifestation of a complete hydatidiform mole. Consequently, medical teams must maintain a high index of suspicion when encountering hypertension in the first or early second trimester. Moreover, the evolution of a mole into gestational trophoblastic neoplasia (GTN) remains a serious risk. Therefore, staging for metastatic disease is mandatory once a diagnosis of GTD is established. In this specific case, the oncology team administered EMA-CO chemotherapy to address the pulmonary lesions. Notably, the patient achieved full disease resolution and subsequently confirmed a viable intrauterine pregnancy only three months after completing treatment.

Effective management relies on a multidisciplinary approach involving obstetricians, oncologists, and critical care specialists. Timely intervention not only resolves the primary malignancy but also preserves future fertility. Physicians should monitor human chorionic gonadotropin (hCG) levels diligently to detect recurrence or persistence. Ultimately, this case proves that even advanced clinical scenarios can result in favorable outcomes with standardized protocols.

Frequently Asked Questions

What causes preeclampsia to develop before 20 weeks?

While preeclampsia usually appears later in pregnancy, its early development strongly suggests gestational trophoblastic disease, such as a hydatidiform mole. Other causes may include antiphospholipid syndrome or pre-existing chronic kidney disease.

Can a patient retain fertility after treatment for metastatic GTN?

Yes. With modern multi-agent chemotherapy like EMA-CO and timely uterine evacuation, many patients successfully achieve subsequent healthy pregnancies. Continuous monitoring of hCG levels remains essential during the follow-up period.

What are the primary symptoms of a complete hydatidiform mole?

Common symptoms include abnormal vaginal bleeding, severe nausea (hyperemesis gravidarum), and a uterus that is larger than expected for the gestational age. Additionally, early-onset hypertension is a classic hallmark of this condition.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Rivera-Hernández DA et al. [Early preeclampsia associated with hydatidiform mole and pulmonary metastasis: A case report]. Rev Med Inst Mex Seguro Soc. 2026 May 06. doi: 10.5281/zenodo.18715459. PMID: 42096254.

Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86-114.

Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11-18.